[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemophilia-a-without-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemophilia-a-without-inhibitor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100608365","the-effects-of-virtual-reality-based-gamified-rehabilitation-in-children-with-hemophilia-100608365",false,"NCT07200609","The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia","The Effects of a Virtual Reality-Based Gamified Rehabilitation Program on Body Structure and Function, Activity, and Participation in Children With Hemophilia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Hemophilia A diagnosed by a pediatric hematologist\n* Boys aged 6-18\n* Have moderate to severe hemophilia\n* Do not exercise regularly\n* Be able to move independently or with minimal support (ambulatory)\n* Have the capacity to understand research instructions\n* Prevent active bleeding\n* Voluntary participation in expenses and parental record keeping\n* Continued prophylactic treatment\n\nExclusion Criteria:\n\n* Children with active bleeding\n* Those who have had lower extremity surgery\n* Those with mental retardation\n* Children with neurological, orthopedic, or psychological illnesses that may affect functional performance","MALE","6 Years","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hemophilia is an inherited bleeding disorder caused by deficiencies or low levels of clotting factors VIII (hemophilia A) and IX (hemophilia B). It is a chronic disease that negatively affects physical function, mobility, and quality of life by causing damage to joint and muscle structures due to bleeding disorders. Traditional rehabilitation methods can sometimes be boring for children and lead to a loss of motivation. Therefore, there is a need for innovative methods that will increase treatment compliance and improve children's physical activity levels.\n\nVirtual reality (VR) technology provides a realistic and interactive environment that enables children to actively participate in the rehabilitation process. Combined with gamification elements, VR offers a fun learning and practice environment that supports the development of motor skills, reduces fear of movement, and can increase motivation for repetitive exercises.\n\nThis randomized controlled trial will evaluate the effects of virtual reality-based gamified rehabilitation on joint health, pain, posture, gait function, proprioception, and quality of life. Additionally, the contribution of this intervention to changes in activity and participation levels will be demonstrated using the International Classification of Functioning, Disability, and Health (ICF) model.\n\nThis study has the potential to guide future clinical practice by offering a more enjoyable and effective rehabilitation alternative for children with hemophilia. The widespread adoption of virtual reality-supported programs will be an important step in reducing physical disabilities associated with hemophilia.",[27],"Hemophilia A Without Inhibitor",[29,30,31,32,33,34],"virtual reality","home-based exercise","joint health","body structure and function","activity","participation","NOT_YET_RECRUITING","2025-09-22",{"date":38,"type":39},"2025-10-01","ACTUAL",{"date":41,"type":21},"2025-11",{"date":43,"type":21},"2026-09",{"name":45,"class":46},"Hacettepe University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100600350","multidimensional-assessment-of-chronic-pain-in-severe-haemophilia-a-100600350","NCT07096349","Multidimensional Assessment of Chronic Pain in Severe Haemophilia A","Multidimensional Assessment of Chronic Pain in Severe Haemophilia A Treated With Monoclonal Antibodies: an Observational Study; an Ambispective Cohort Study","Inclusion Criteria:\n\n* Patients over 18 years of age.\n* With a medical diagnosis of severe haemophilia A (FVIII \\\u003C 1%).\n* No inhibitors to FVIII concentrates at the time of the study.\n* At least 3 months of treatment with bispecific monoclonal antibodies.\n* Medical diagnosis of haemophilic arthropathy in at least two lower limb joints and ≥5 points on the Haemophilia Joint Health Score.\n* Ability to understand and respond to self-administered questionnaires.\n\nExclusion Criteria:\n\n* Patients diagnosed with severe musculoskeletal or neurological comorbidities causing chronic pain.\n* Individuals with neurological or cognitive impairments that prevent them from understanding the questionnaires.\n* Patients who have participated in an interventional clinical study in the 6 months prior to the study.",{"count":55,"type":21},109,"OBSERVATIONAL","Introduction: Haemophilia is a congenital coagulopathy characterised by haemarthrosis, mainly in the knees, ankles and elbows. Prophylactic treatment is the most effective therapeutic option for preventing or minimising these bleeds. Bispecific monoclonal antibodies have been shown to be effective in reducing bleeding in patients with haemophilia.\n\nObjectives: To investigate the associations between chronic residual pain and pain catastrophising, perceived self-efficacy regarding the disease and treatment, and body image and perception of visible disability.\n\nMethods. Multicentre cross-sectional cohort studies. 109 patients with severe haemophilia A from different regions of Spain will be included in the study. The primary variable will be chronic residual pain and its functional interference (Brief Pain Inventory-Short Form). Secondary variables will be pain catastrophising (Pain Catastrophising Scale), perceived self-efficacy regarding the disease and treatment (Pain Self-Efficacy Questionnaire), and body image and perception of visible disability (Body Image Scale). Potential confounding variables will include sociodemographic variables (age and educational level), clinical variables (time on monoclonal antibody treatment and number of previous bleeds in the last 12 months) and anthropometric variables (body mass index).\n\nExpected results: It is expected that residual chronic pain will persist in patients with severe haemophilia A treated with monoclonal antibodies and that it will be associated with greater catastrophising, lower self-efficacy and poorer body image, modulating the experience of pain beyond bleeding control.",[27],[60,61,62,63,64,65],"Hemophilia","Bispecific monoclonal antibodies","Chronic pain","Catastrophising","Self-efficacy","Body image","RECRUITING","2025-07-31",{"date":69,"type":39},"2025-08-01",{"date":71,"type":21},"2025-07-30",{"date":73,"type":21},"2025-10-26",{"name":75,"class":76},"Investigación en Hemofilia y Fisioterapia","NETWORK",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100540729","phase-4-pharmacokinetic-guided-dosing-of-emicizumab-100540729","NCT06320626","Pharmacokinetic-guided Dosing of Emicizumab","Pharmacokinetic-guided Dosing of Emicizumab in Congenital Haemophilia A Patients - The DosEmi Study","DosEmi","Inclusion Criteria:\n\n* Confirmed diagnosis of congenital haemophilia A, with a baseline endogenous FVIII of \\\u003C6 IU\u002Fml\n* Aged \\> 1 year at inclusion (inclusion of children 1-16 years after favourable interim-analysis see protocol)\n* Receiving conventional dosing of emicizumab (6 mg\u002Fkg\u002F4 weeks with varying intervals) for a duration of at least 12 months prior to inclusion;\n* Having good bleeding control, defined as:\n\ni No spontaneous joint\u002Fmuscle bleeds in the previous 6 months AND ii A maximum of two treated (traumatic) bleeds in the previous 6 months.\n\n* Willing and able to provide written informed consent, either by the subject or its parents\u002Flegal guardian\n* Willing to provide bleeding assessment information\n* Willing to adhere to the medication regimen\n\nExclusion Criteria:\n\n* Acquired haemophilia A","1 Year",{"count":88,"type":21},95,[90],"PHASE4","The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.",[93,27,94,95,96,97],"Hemophilia A With Inhibitor","Hemophilia A, Severe","Adolescent","Child","Adult",[99,100,101,102,103],"Emicizumab","Hemophilia A","Monoclonal antibodies","PK-guided dosing","Hemorrhage","2024-03-12",{"date":106,"type":39},"2024-03-20",{"date":108,"type":39},"2022-09-08",{"date":110,"type":21},"2026-08",{"name":112,"class":46},"Kathelijn Fischer",8]